Cerevel Therapeutics Holdings Inc (NAS:CERE)
$ 42.21 -0.09 (-0.21%) Market Cap: 7.69 Bil Enterprise Value: 7.21 Bil PE Ratio: 0 PB Ratio: 13.62 GF Score: 40/100

Q3 2022 Cerevel Therapeutics Holdings Inc Earnings Call Transcript

Nov 08, 2022 / 01:00PM GMT
Release Date Price: $25.7 (-5.20%)
Operator

Good morning, and welcome to the Cerevel Therapeutics Third Quarter 2022 Financial Results Conference Call. (Operator Instructions) Please note that this call may be recorded. I will now hand the call over to Matt Calistri, Vice President of Investor Relations. Please go ahead.

Matthew Calistri
Cerevel Therapeutics Holdings, Inc. - VP of IR

Thank you. Thank you. Good morning, everyone. We appreciate you joining us for our third quarter 2022 earnings call. On today's call, you'll be hearing from Dr. Tony Coles, our Chairperson and Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Mark Bodenrader, our Interim Chief Financial Officer. Abraham Ceesay, our President, will join us for Q&A. During our call today, please refer to our press release from this morning, detailing our Q3 2022 performance as well as our updated corporate presentation, both of which are available on our website.

I would like to remind you that we will be making forward-looking statements that reflect our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot